| B11 | High rate of successful outcomes treating highly resistant TB in the ZeNix study of pretomanid, bedaquiline and alternative doses and durations of linezolid | Oral abstract session with live Q&A | Tuberculosis and other mycobacteria |
| B10 | Single high-dose liposomal amphotericin based regimen for treatment of HIV-associated Cryptococcal Meningitis: results of the phase-3 Ambition-cm Randomised Trial | Oral abstract session with live Q&A | Opportunistic infections (excluding tuberculosis) |
| B78 | Unsuppressed plasma HIV-RNA viral load is associated with worse COVID-19 outcomes among people living with HIV | Oral abstract session with live Q&A | COVID-19 morbidity and mortality in PLWH |
| B39 | Long-acting subcutaneous lenacapavir dosed every 6 months as part of a combination regimen in treatment-naïve people with HIV: interim 16-week results of a randomized, open-label, phase 2 induction-maintenance study (CALIBRATE) | Oral abstract session with live Q&A | Long-acting agents and other drug delivery systems |
| B35 | Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA) | Oral abstract session with live Q&A | Regimen simplification and switch studies |
| B6 | More frequent viral load testing, with point-of-care tests has no impact on viral suppression in postpartum HIV-positive women in a randomized controlled trial in 2 clinics in Johannesburg, South Africa | Oral abstract session with live Q&A | Viral load and CD4 measurement |
| B63 | Obsession with suppression: comparison of virally suppressed and unsuppressed children and adolescents living with HIV (CALHIV) treated with dolutegravir regimens in Mbeya and Mwanza, Tanzania | Oral abstract session with live Q&A | Adherence in paediatric and adolescent populations |
| B7 | A rapid enzymatic assay for selective detection of HIV drugs that indicate long-term and short-term PrEP adherence | Oral abstract session with live Q&A | ART adherence measurement |
| C32 | Adherence to the dapivirine vaginal ring and oral PrEP among adolescent girls and young women in Africa: interim results from the REACH study | Oral abstract session with live Q&A | Novel delivery systems (e.g., rings, implants, transdermal systems) |
| C21 | High rates of drug resistance in individuals diagnosed with HIV in tenofovir disoproxil fumarate (TDF)-based pre-exposure prophylaxis rollout programs in Kenya, Zimbabwe, Eswatini and South Africa | Oral abstract session with live Q&A | Surveillance of drug resistance in the era of PrEP |